Waycross Partners LLC Sells 7,447 Shares of Edwards Lifesciences Co. (NYSE:EW)

Waycross Partners LLC decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 5.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,321 shares of the medical research company’s stock after selling 7,447 shares during the period. Edwards Lifesciences comprises about 1.8% of Waycross Partners LLC’s investment portfolio, making the stock its 26th biggest holding. Waycross Partners LLC’s holdings in Edwards Lifesciences were worth $9,403,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. AustralianSuper Pty Ltd purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $168,519,000. Nordea Investment Management AB grew its holdings in Edwards Lifesciences by 1,224.1% during the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after acquiring an additional 1,488,791 shares during the period. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares during the period. FMR LLC boosted its stake in shares of Edwards Lifesciences by 61.1% in the third quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock worth $215,557,000 after acquiring an additional 1,179,637 shares during the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the third quarter valued at $60,971,000. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 7,250 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total value of $622,050.00. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,636,549.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,250 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total value of $622,050.00. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,636,549.20. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 201,254 shares of company stock valued at $17,788,304. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

NYSE EW traded down $1.27 on Tuesday, hitting $84.68. The stock had a trading volume of 3,097,272 shares, compared to its average volume of 3,828,306. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The company has a market capitalization of $50.97 billion, a price-to-earnings ratio of 36.50, a price-to-earnings-growth ratio of 4.28 and a beta of 1.05. The firm has a 50-day moving average of $90.23 and a 200-day moving average of $79.16.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Equities analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on EW. Oppenheimer boosted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Piper Sandler upped their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Royal Bank of Canada increased their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $92.71.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.